USA - engelska - NLM (National Library of Medicine)

par pharmaceuticals, inc. - dexmethylphenidate hydrochloride (unii: 1678ok0e08) (dexmethylphenidate - unii:m32rh9mfgp) - dexmethylphenidate hydrochloride 15 mg - dexmethylphenidate hydrochloride extended-release capsules is indicated for the treatment of attention deficit hyperactivity disorder (adhd) [see clinical studies (14)] . - hypersensitivity to methylphenidate or other components of dexmethylphenidate hydrochloride extended-release capsules. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate [see adverse reactions (6.1)] . - concomitant treatment with monoamine oxidase inhibitors (maois) or within 14 days following discontinuation of treatment with an maoi, because of the risk of hypertensive crises [see drug interactions (7.1)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including dexmethylphenidate hydrochloride extended-release capsules, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for adhd medications at 1-

USA - engelska - NLM (National Library of Medicine)

virtus pharmaceuticals - chlordiazepoxide hydrochloride (unii: mfm6k1xwdk) (chlordiazepoxide - unii:6rz6xez3cr), clidinium bromide (unii: 91zqw5jf1z) (clidinium - unii:bo76jf850n) - chlordiazepoxide hydrochloride 5 mg - chlordiazepoxide hydrochloride/clidinium bromide is indicated to control the emotional and somatic factors in gastrointestinal disorders. chlordiazepoxide hydrochloride/clidinium bromide may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. chlordiazepoxide hydrochloride/clidinium bromide is contraindicated in the presence of glaucoma (since the anticholinergic component may produce some degree of mydriasis) and in patients with prostatic hypertrophy and benign bladder neck obstruction. it is contraindicated in patients with known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of chlordiazepoxide. the more severe withdrawal symptoms have

Irland - engelska - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - glucose monohydrate soya oil triglycerides isoleucine leucine lysine hydrochloride dl-methionine phenylalanine threonine tryptophan, l- valine arginine histidine hyprochloride monohydrate alanine aspartic acid glutamic acid aminoacetic acid proline serine - emulsion for infusion - per cent

Australien - engelska - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - epirubicin hydrochloride is used in the treatment of: - breast, ovarian, stomach, lung and colorectal cancer - malignant lymphoma e.g. hodgkin's disease and non-hodgkin's lymphoma - multiple myeloma - non-invasive bladder cancer epirubicin is also used to help prevent recurrence of bladder cancer after surgery.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - thallous(201tl) chloride, quantity: 125 mbq/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; benzyl alcohol - thallous chloride (201tl) may be useful in myocardial perfusion imaging for the diagnosis and localization of myocardial infarction. it may also be useful in conjunction with exercise stress testing as an adjunct in the diagnosis of ischaemic heart disease (atherosclerotic coronary artery disease).

Israel - engelska - Ministry of Health

lapidot medical import and marketing ltd - sodium chloride - solution for injection - sodium chloride 9 mg/ml - sodium chloride - sodium chloride - short - term intravascular volume substitution. hypotonic dehydration or isotonic dehydration.vehicle solution for supplementary medication.fluid and electrolyte replacement, hypochloremic alkalosis and chloride losses.externally for wound irrigation and moistening of wound tamponade dressings.

Israel - engelska - Ministry of Health

lapidot medical import and marketing ltd - sodium chloride - solution for injection - sodium chloride 0.9 g / 100 ml - sodium chloride - sodium chloride - short - term intravascular volume substitution. hypotonic dehydration or isotonic dehydration.vehicle solution for supplementary medication.fluid and electrolyte replacement, hypochloremic alkalosis and chloride losses.externally for wound irrigation and moistening of wound tamponade dressings.

Israel - engelska - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Israel - engelska - Ministry of Health

lapidot medical import and marketing ltd - sodium chloride - solution for injection - sodium chloride 0.9 g / 100 ml - sodium chloride - sodium chloride - short - term intravascular volume substitution. hypotonic dehydration or isotonic dehydration.vehicle solution for supplementary medication.fluid and electrolyte replacement, hypochloremic alkalosis and chloride losses.externally for wound irrigation and moistening of wound tamponade dressings.

Israel - engelska - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.